/
 Managing CINV and Cachexia  Managing CINV and Cachexia

Managing CINV and Cachexia - PowerPoint Presentation

min-jolicoeur
min-jolicoeur . @min-jolicoeur
Follow
344 views
Uploaded On 2020-04-06

Managing CINV and Cachexia - PPT Presentation

Program Goals Concepts and Definitions for Supportive Care and Palliative Care Supportive Care and Palliative Care Supportive Care and Palliative Care cont Supportive Care and Palliative Care cont ID: 776209

cont references romana care cont references romana care nepa palliative supportive safety related cancer efficacy rolapitant design cachexia analysis

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document " Managing CINV and Cachexia" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Managing CINV and Cachexia

Slide2

Program Goals

Slide3

Concepts and Definitions for “Supportive Care” and “Palliative Care”

Slide4

Supportive Care and Palliative Care

Slide5

Supportive Care and Palliative Care (cont)

Slide6

Supportive Care and Palliative Care (cont)

Slide7

Cancer-Related Cachexia

Slide8

Definition and Classification of Cancer-Related CachexiaAn International Consensus

Slide9

New Avenues of Investigation for Treatment of Cancer-Related Cachexia

Slide10

ROMANA 1 and ROMANA 2Phase 3 Study Design

Slide11

ROMANA 1 and ROMANA 2 Efficacy Results: Co-Primary End Points

Slide12

ROMANA 1 and ROMANA 2Efficacy and Safety

Slide13

Rolapitant

Slide14

Rolapitant (cont)

Slide15

Rolapitant: Regional DifferencesSubgroup Analysis of HEC Study

Slide16

NEPA

Slide17

NEPA (cont)

Slide18

NEPA + DEX: Overall CR Rate by Gender/AgePooled Analysis of Patients Receiving HEC in 3 Pivotal Studies

Slide19

NEPA: Maintenance of Control Over 4 CyclesPooled Analysis From 2 Studies

Slide20

NEPA

Slide21

Aprepitant in ChildrenPhase 3 Trial Design

Slide22

Aprepitant in Children (cont)Efficacy and Safety

Slide23

Palonosetron vs Ondansetron in ChildrenPhase 3 Trial Design

Slide24

Palonosetron vs Ondansetron in Children (cont)Efficacy and Safety

Slide25

Summary

Slide26

Abbreviations

Slide27

Abbreviations (cont)

Slide28

References

Slide29

References (cont)

Slide30

References (cont)

Slide31

References (cont)

Slide32

References (cont)

Slide33

References (cont)

Slide34

References (cont)